Liposomal paclitaxel formulations

Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00027162%3A_____%2F12%3A%230000927" target="_blank" >RIV/00027162:_____/12:#0000927 - isvavai.cz</a>
Result on the web
<a href="http://dx.doi.org/10.1016/j.jconrel.2012.09.006" target="_blank" >http://dx.doi.org/10.1016/j.jconrel.2012.09.006</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1016/j.jconrel.2012.09.006" target="_blank" >10.1016/j.jconrel.2012.09.006</a>

Result language
angličtina
Original language name
Liposomal paclitaxel formulations
Original language description
Over the past three decades, taxanes represent one of the most important new classes of drugs approved in oncology. Paclitaxel (PTX), the prototype of this class, is an anti-cancer drug approved for the treatment of breast and ovarian cancer. However, notwithstanding a suitable premedication, present-day chemotherapy employing a commercial preparation of PTX (Taxol (R)) is associated with serious side effects and hypersensitivity reactions. Liposomes represent advanced and versatile delivery systems fordrugs. Generally, both in vivomice tumor models and human clinical trials demonstrated that liposomal PTX formulations significantly increase a maximum tolerated dose (MTD) of PTX which outperform that for Taxol (R). Liposomal PTX formulations are in various stages of clinical trials. LEP-ETU (NeoPharm) and EndoTAG (R)-1 (Medigene) have reached the phase II of the clinical trials; Lipusu (R) (Luye Pharma Group) has already been commercialized. Present achievements in the preparation of
Czech name
—
Czech description
—

Type
J<sub>x</sub> - Unclassified - Peer-reviewed scientific article (Jimp, Jsc and Jost)
CEP classification
FR - Pharmacology and apothecary chemistry
OECD FORD branch
—

Project
Result was created during the realization of more than one project. More information in the Projects tab.
Continuities
P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)<br>Z - Vyzkumny zamer (s odkazem do CEZ)

Publication year
2012
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Similar results(10)